SCHEMBL7101613

SCHEMBL7101613

COC(=O)c1ccc2c(c1)c(=O)n(Cc1cccc(F)c1)c(=O)n2C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 3/20 0.50
TP53 P04637 2/20 0.49
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MMP13 P45452 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
MAPT P10636 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102220 0.89 POLB (0.52) PARGTP53POLBSMN1; SMN2HDAC1
SCHEMBL27588034 0.88 PARG (0.52) PARGTP53SMN1; SMN2MMP13SLC22A8
SCHEMBL6255189 0.88 MMP13 (0.58) PARGTP53POLBMMP13SLC22A8
SCHEMBL6245488 0.88 MMP13 (0.60) PARGTP53MMP13SLC22A8HDAC1
SCHEMBL7105312 0.86 PARG (0.48) PARGTP53SMN1; SMN2MMP13SLC22A8
SCHEMBL27588009 0.84 PARG (0.54) PARGTP53SMN1; SMN2MMP13SLC22A8
SCHEMBL7181983 0.84 PARG (0.48) PARGTP53SMN1; SMN2MMP13SLC22A8
SCHEMBL6258761 0.83 MAPT (0.58) TP53POLBSMN1; SMN2MMP13MAPT
SCHEMBL6254595 0.83 POLB (0.54) TP53POLBSMN1; SMN2MMP13MAPT
SCHEMBL27588029 0.83 PARG (0.52) PARGTP53MMP13SLC22A8HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1537105-A Quinazolines useful as MMP-13 inhibitors ��������ʲ��������ι�˾ 2004-10-13 CN disclosed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 PARG 3624/4885TP53 4351/4885POLB 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.